Methcathinone Stats & Data

Injecting or otherwise using methcathinone made with potassium permanganate (a common home synthesis) has been repeatedly linked to irreversible manganese-induced parkinsonism; avoid any preparation of uncertain origin and never inject — Mn-related damage does not improve after cessation. Early signs include gait disturbance, hypophonia, and falls; MRI classically shows T1 hyperintensity of the globus pallidus. Redosing pressure is high due to the short duration; spacing doses and setting a firm session cap reduces binge risk and sleep deprivation. Like other stimulants, methcathinone can acutely raise heart rate and blood pressure; those with cardiovascular disease, hypertension, or arrhythmia risk should avoid use and everyone should avoid strenuous exertion while under the influence. Combining with MAOIs is hazardous (hypertensive crises, hyperthermia) and should be strictly avoided; combining with tramadol or bupropion increases seizure risk. Mixing with alcohol increases dehydration and cardiostress while masking intoxication; with benzodiazepines, sedation can mask stimulant overuse and encourage redosing — treat as a caution-only combination reserved for managing severe agitation. Insufflation is irritating/caustic; use tiny test lines, rotate nostrils, rinse with saline after, and allow mucosa to recover between sessions. Use a precise milligram scale, lab‑verified material when possible, and consider reagent testing/drug checking to rule out substitutions or manganese contamination. Expect a comedown (anxiety, dysphoria, insomnia); nutrition, hydration, and planning sleep ahead of time reduce harm. Frequent use builds tolerance rapidly and can drive dose escalation; spacing sessions (≥1–2 weeks) reduces risk of dependency and persistent mood changes.